Welcome to our dedicated page for Greenwich LifeSciences news (Ticker: GLSI), a resource for investors and traders seeking the latest updates and insights on Greenwich LifeSciences stock.
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) is a clinical-stage biopharmaceutical company dedicated to the development of groundbreaking immunotherapies aimed at preventing breast cancer recurrences. The company's flagship product, GP2, is an immunotherapy designed to stimulate the body's immune system to target and eliminate HER2/neu-expressing cancer cells, particularly in patients who have already undergone surgery for breast cancer.
GP2 leverages the HER2/neu transmembrane peptide to elicit a targeted immune response, providing a promising approach to cancer treatment. Another significant component of their pipeline is the GM-CSF Immunoadjuvant, which has shown potential in enhancing monocyte and neutrophil cytotoxicity against melanoma tumor cells, as well as boosting activity-dependent cellular cytotoxicity against targets coated with anti-ganglioside antibodies.
The company’s ongoing clinical trials are a testament to its commitment to innovation and excellence in cancer treatment. These trials are being conducted in collaboration with a steering committee comprising esteemed members from various medical institutions, ensuring rigorous oversight and adherence to the highest standards of clinical research.
Greenwich LifeSciences places a strong emphasis on advancing cancer immunotherapy to selectively stimulate an individual's immune system to attack cancer cells, thereby inhibiting the spread of the disease. Their work not only focuses on breast cancer but extends to other cancer types, showcasing a broad potential for impact in oncology.
With a robust pipeline, strategic partnerships, and a clear focus on unmet medical needs, Greenwich LifeSciences is poised to be a leader in the biopharmaceutical industry. Investors and stakeholders can stay updated on the latest developments and company performance through regular news updates and reports.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced that CEO Snehal Patel will be interviewed live on Benzinga’s Power Hour on March 11, 2021. During the 15-20 minute segment, Mr. Patel will discuss the successful Phase IIb clinical trial of GP2, an immunotherapy with 0% breast cancer recurrences observed over 5 years. He will also outline plans for a Phase III trial and key upcoming milestones. GP2 targets HER2/neu positivity, aiming to prevent breast cancer recurrences in post-surgery patients. The company has reported no serious adverse events in 138 treated patients thus far.
Greenwich LifeSciences (Nasdaq: GLSI) has appointed Jaye Thompson, PhD, as Vice President of Clinical and Regulatory Affairs to spearhead the GP2 Phase III clinical trial aimed at preventing breast cancer recurrences. Dr. Thompson emphasizes the urgency for effective treatments for the 3 million U.S. breast cancer survivors. Notably, GP2's Phase IIb trial reported no recurrences over five years in treated patients. The company aims to replicate these promising results in the upcoming trial, with plans to engage multiple sites and optimize resource allocation for clinical and regulatory proceedings.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced CEO Snehal Patel's participation in several virtual investor conferences in March 2021. Notable events include the H.C. Wainwright Global Life Sciences Conference on March 9, the Landmark Health Innovations Conference on March 11, and the BIO-Europe Spring from March 22-25. The company also plans to present at the Benzinga Biotech Small-Cap Conference on March 25. Greenwich LifeSciences focuses on GP2, an immunotherapy aimed at preventing breast cancer recurrences, reporting no recurrences in a recent clinical trial with 138 patients.
Greenwich LifeSciences (Nasdaq: GLSI) announced acceptance of two abstracts for presentation at the AACR Annual Meeting 2021. The presentations will highlight GP2, an immunotherapy designed to prevent breast cancer recurrences. The first abstract discusses the final 5-year immune response analysis from the Phase IIb trial, which showed a 0% recurrence rate in HER2/neu 3+ patients. The second abstract outlines the design of the upcoming Phase III clinical trial, aiming for FDA conditional marketing approval based on interim results.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced that its underwriter has purchased an additional 70,000 shares at $40.00 each in a public offering, bringing total gross proceeds to approximately $29.2 million. The offering was facilitated by Aegis Capital Corp. The SEC declared the registration statement for the shares effective on December 17, 2020. Greenwich LifeSciences is focused on developing GP2, an immunotherapy for preventing breast cancer recurrences, with a Phase III trial planned following a successful Phase IIb trial with promising results.
Greenwich LifeSciences (Nasdaq: GLSI) announced an exclusive interview with CEO Snehal Patel on The RedChip Money Report, airing on Bloomberg International. Patel highlights GP2's development, an immunotherapy targeting breast cancer recurrence, which showcased 0% recurrences in a Phase IIb trial after 5 years. The interview covers planned Phase III trials and key milestones. Greenwich LifeSciences aims to combat invasive breast cancer, with GP2 demonstrating tolerance in 138 patients across trials.
Greenwich LifeSciences (Nasdaq: GLSI) announced CEO Snehal Patel's participation in upcoming virtual investor conferences. The conferences will highlight GP2 trial data aimed at preventing breast cancer recurrences. Key events include: B. Riley Securities Oncology Investor Conference on January 21, 2021, and the BIO CEO & Investor Conference from February 16-18, 2021, featuring networking opportunities with investors. GP2 shows promising Phase IIb results, with no recurrences in 3+ HER2 patients after 5 years. Visit greenwichlifesciences.com for more details.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced that its CEO, Snehal Patel, will participate in three virtual investor conferences during the week of January 11, 2021. These include the H.C. Wainwright BioConnect Conference with an on-demand presentation starting at 6:00 am EST, the Biotech Showcase 2021, and the BIO Partnering event at the 2021 JP Morgan Healthcare Conference. The company’s GP2 immunotherapy aims to prevent breast cancer recurrences in patients post-surgery, showing promising Phase IIb trial results with no recurrences in a specific patient group after five years.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced that the replay of its December 15, 2020 presentation at the LD Micro Main Event is now available. CEO Snehal Patel highlighted the successful Phase IIb trial of GP2, which showed a remarkable 100% disease-free survival rate in HER2 positive patients over five years. The company plans to initiate a Phase III trial to further investigate GP2 as an immunotherapy for preventing breast cancer recurrences. For further details, the replay can be accessed through their website.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) will ring the Nasdaq opening bell on December 28, 2020, to celebrate its IPO completion. CEO Snehal Patel and the team will participate in a virtual ceremony starting at 9:20 am EST. The company has raised over $33 million to fund its GP2 immunotherapy aimed at preventing breast cancer recurrences. The Phase III clinical trial is set to commence, following positive results from a Phase IIb trial where no recurrences were observed in the HER2/neu 3+ adjuvant setting. This initiative aims to improve outcomes for breast cancer survivors.
FAQ
What is the current stock price of Greenwich LifeSciences (GLSI)?
What is the market cap of Greenwich LifeSciences (GLSI)?
What is Greenwich LifeSciences, Inc.?
What is GP2?
What does the GM-CSF Immunoadjuvant do?
What types of cancer is Greenwich LifeSciences targeting?
Who oversees the clinical trials at Greenwich LifeSciences?
What is the significance of HER2/neu in cancer treatment?
Are there any ongoing clinical trials?
How can investors stay updated on the company?
What makes Greenwich LifeSciences' approach unique?
Where can I find more information about Greenwich LifeSciences?
